Clinical Trial Update: A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety and efficacy of PRM-151 (rhPTX-2) for idiopathic pulmonary fibrosis was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PRM-151 (recombinant human pentraxin-2)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-05-16